Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background: The aim of this study was to investigate the efficacy of exenatide and insulin glargine in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). Methods: We performed a 24‐week randomized controlled multicentre clinical trial. Seventy‐six patients were randomly assigned 1:1 to receive exenatide or insulin glargine treatment. The endpoints included changes in liver fat content (LFC), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) measured by magnetic resonance spectroscopy, blood glucose, liver enzymes, lipid profile, body weight, and Fibrosis‐4 index (FIB‐4). Results: LFC, VAT, SAT, and FIB‐4 were significantly reduced after exenatide treatment (ΔLFC, −17.55 ± 12.93%; ΔVAT, −43.57 ± 68.20 cm 2; ΔSAT, −28.44 ± 51.48 cm 2; ΔFIB‐4, −0.10 ± 0.26; all P < .05). In comparison, only LFC (ΔLFC, −10.49 ± 11.38%; P < .05), and not VAT, SAT, or FIB‐4 index (all P > .05), was reduced after insulin glargine treatment. Moreover, exenatide treatment resulted in greater reductions in alanine transaminase (ALT), aspartate transaminase (AST), and gamma glutamyl transpeptidase (GGT) than insulin glargine (P < 0.05). The body weight, waist circumference, postprandial plasma glucose, and low‐density lipoprotein cholesterol (LDL‐C) in the exenatide group also presented greater reductions than the insulin glargine group (P < .05). The proportion of adverse events were comparable between the two groups. Conclusion: Both exenatide and insulin glargine reduced LFC in patients with drug‐naive T2DM and NAFLD; however, exenatide showed greater reductions in body weight, visceral fat area, liver enzymes, FIB‐4, postprandial plasma glucose, and LDL‐C.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids
Vatner, D. F., Majumdar, S. K., Kumashiro, N., Petersen, M. C., Rahimi, Y., Gattu, A. K., Bears, M., Camporez, J.-P. G., Cline, G. W., Jurczak, M. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423952112 · Cited by 235 · cited 1×
“It has been demonstrated that hepatic fat accumulation was driven mainly by esterification of FFAs and availability of peripheral FFA rather than insulin-mediated hepatic de novo lipogenesis.(30) In addition, our multivariate regression analysis showed that reductions in circulating FFA and TG were independently corre…”
MethodCuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050117 · Cited by 226 · cited 1×
“5% and insulin glargine decreased LFC by about 3 ± 3%.(14,18) We estimated”
BackgroundShao, N., Kuang, H. Y., Hao, M., Gao, X. Y., Lin, W. J., & Zou, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2561 · Cited by 185 · cited 10×
“It is well known that NAFLD is associated with increased levels of serum TGs, independent of other factors.36 Our study showed that both exenatide and insulin glargine significantly reduced TGs. Multiple linear regression analysis showed that ΔTG was independently associated with ΔLFC in T2DM with NAFLD.”
BackgroundInfluentialSelf-citationJuurinen, L., Tiikkainen, M., Häkkinen, A.-M., Hakkarainen, A., & Yki-Järvinen, H. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2006 · Cited by 141 · cited 1×
“5% and insulin glargine decreased LFC by about 3 ± 3%.(14,18) We estimated”
BackgroundEffects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes
Sathyanarayana, P., Jogi, M., Muthupillai, R., Krishnamurthy, R., Samson, S. L., & Bajaj, M. (2011) · Obesity · doi:10.1038/oby.2011.152 · Cited by 124
Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
Fan, H., Pan, Q., Xu, Y., & Yang, X. (2013) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302013000900005 · Cited by 122 · cited 1×
“A study of 117 patients with poorly controlled T2DM and NAFLD showed that exenatide improved ALT, AST, and GGT compared with metformin.(31) Bi et al(17) found that exenatide could slightly reduce ALT, but there was no significant difference compared with other treatment groups.”
Result
Cited by
Badmus, O. O., Hillhouse, S. A., Anderson, C. D., Hinds, T. D., & Stec, D. E. (2022) · Clinical Science · doi:10.1042/cs20220572 · Cited by 370
Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G. (2021) · Metabolites · doi:10.3390/metabo11020073 · Cited by 299
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 301
Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Newsome, P. N., & Ambery, P. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.033 · Cited by 211
Hepatic glucose metabolism in the steatotic liver
Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00888-8 · Cited by 134
“Table 2 shows a summary of the main results in MASLD obtained following treatment with a single GLP1RA, including short-acting exenatide 174,181–185 , liraglutide 173,186,187 and lixisenatide 188 , and long-acting GLP1RA semaglutide 189 and dulaglutide 190 ; DPP4 inhibitors, such as sitagliptin,…”
Guo, W., Tian, W., Lin, L., & Xu, X. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108487 · Cited by 126
Targher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00338-7 · Cited by 121
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Liao, C., Liang, X., Zhang, X., & Li, Y. (2023) · PLOS ONE · doi:10.1371/journal.pone.0289616 · Cited by 63
“2020 [37] 32 36 Exenatide 10μg BID Insulin Glargine 24 49.”
Metabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023) · Diabetologia · doi:10.1007/s00125-023-05966-9 · Cited by 44
Camilleri, M., & Lupianez-Merly, C. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002519 · Cited by 41
Incretin-based investigational therapies for the treatment of MASLD/MASH
Brouwers, B., Rao, G., Tang, Y., Rodríguez, Á., Glass, L. C., & Hartman, M. L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111675 · Cited by 40
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30
Liu, F., Yang, Q., Zhang, H., Zhang, Y., Yang, G., Ban, B., Li, Y., & Zhang, M. (2022) · PLOS ONE · doi:10.1371/journal.pone.0270899 · Cited by 30
Metadata
- Authors
- Liu, L., Yan, H., Xia, M., Zhao, L., Lv, M., Zhao, N., Rao, S., Yao, X., Wu, W., Pan, B., Bian, H., & Gao, X.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2020-02-10
- Volume
- 36
- Issue
- 5
- Pages
- e3292-e3292
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2999377366
- Cited by
- 118
- References
- 12
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.